Olaparib (new indication: high risk early breast cancer with BRCA1/2-mutations and HER2-negative as monotherapy or in combination with endocrine therapy for the adjuvant treatment of previously treated patients)



  • Active Sustance: Olaparib
  • Name: Lynparza®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: AstraZeneca GmbH


Time table:

  • Start: 01.09.2022
  • Publication of assessment: 01.12.2022
  • End of public hearing: 22.12.2022
  • Final decision by G-BA: middle of February 2023


Comparative therapy:

  • Watchful waiting